impression healthcare - search results
If you're not happy with the results, please do another search
Impression Healthcare to focus exclusively on cannabinoid sales and drug development
Medical cannabis company Impression Healthcare (ASX: IHL) has announced it will discontinue sales of its oral devices by the end of the month to focus its resources exclusively on cannabinoid sales an...
Impression Healthcare starts CBD drug trial to fight leading cause of COVID-19 deaths
Impression Healthcare (ASX: IHL) has begun the first clinical trial to assess the effectiveness of its cannabidiol (CBD) based drug IHL-675A against sepsis associated acute respiratory distress syndro...
Impression Healthcare recruits NRL star James Graham to boost commercial development of IHL-216A
Medical cannabis company Impression Healthcare (ASX: IHL) has unveiled a high profile acquisition in the form of professional rugby league footballer James Graham.
In a statement to the market this m...
Impression Healthcare to commence animal testing of CBD drug for COVID-19 related respiratory conditions
Impression Healthcare (ASX: IHL) has confirmed in it quarterly report that it has sourced all permits and products required for the start of animal pre-clinical testing of cannabinoid drug IHL-675A de...
Impression Healthcare targets 2024 commercialisation of cannabinoid treatment for traumatic brain injury
Medical cannabis company Impression Healthcare (ASX: IHL) has confirmed plans to bring its novel cannabinoid formula IHL-216A for patients with traumatic brain injury to the prescription market within...
Impression Healthcare develops CBD-based drug as potential treatment for coronavirus symptoms
Medicinal cannabis company Impression Healthcare (ASX: IHL) has developed a cannabidiol (CBD) based drug that it believes holds potential for the treatment of coronavirus-induced respiratory distress ...
Impression Healthcare sets out FDA approval strategy for cannabinoid drug candidate IHL-42X
Medical cannabis company Impression Healthcare (ASX: IHL) has revealed it has received an independent strategic assessment report on the FDA approval pathway for cannabinoid IHL-42X from US-based Cama...
Impression Healthcare acquires CBD inhalers for distribution under Australia’s Special Access Scheme
Medical cannabis company Impression Healthcare (ASX: IHL) came out of a trading halt late this morning to unveil an initial order for cannabidiol (CBD) pressurised metered-dose inhalers (similar to an...
Impression Healthcare to launch medical cannabis trials for treatment of traumatic brain injury
Australian medical cannabis company Impression Healthcare (ASX: IHL) has finalised the design of a clinical program to assess novel cannabinoid formula IHL-216A on neurocognitive function after trauma...
Impression Healthcare expands cannabinoid oil sales program
Medical cannabis company Impression Healthcare (ASX: IHL) has expanded its cannabinoid oil sales program that runs side by side with its extensive base of clinical trial projects.
In a statement to...
Impression Healthcare prepares for obstructive sleep apnoea clinical trial
Medical cannabis company Impression Healthcare (ASX: IHL) is on course to begin a clinical trial using its IHL-42X drug candidate for the treatment of obstructive sleep apnoea.
The drug was recentl...
Impression Healthcare files patent for non-intrusive treatment of obstructive sleep apnoea
Medical cannabis company Impression Healthcare (ASX: IHL) is continuing on its path to developing an effective solution for obstructive sleep apnoea (OSA) having filed a patent application covering IH...
Impression Healthcare recruits Big Pharma executive to complete cannabinoid drug discovery goal
Medical cannabis company Impression Healthcare (ASX: IHL) has continued its top-tier recruitment drive with the addition of yet another pharmaceutical industry expert into its ranks.
Former Roche (...
Impression Healthcare AGM presentation from chief medical officer Dr Sud Agarwal
Dr Sud Agarwal presented at Impression Healthcare's (ASX: IHL) annual general meeting on Friday 4th October 2019 to discuss Incannex's portfolio.
Under the guidance of Impression's new medical advi...
Impression Healthcare files patent application for medicinal CBD drug to alleviate concussion injuries
Impression Healthcare (ASX: IHL) has opted to file a patent application for a neuroprotective agent that could potentially aid people that suffer concussions – a growing issue in contact sports such a...
Duo of renowned specialists join Impression Healthcare, Incannex CBD oils on route
Following a busy few months on the recruitment and brand licencing fronts, Impression Healthcare (ASX: IHL) has appointed an additional duo of leading medical experts to its Medical Advisory Board, ov...
Impression Healthcare appoints two globally renowned medical experts for cannabis medicines projects
Impression Healthcare (ASX: IHL) has bolstered its Medical Advisory Board by appointing two leading medical experts possessing extensive expertise within two key market niches currently being explored...
Impression Healthcare commences obstructive sleep apnoea clinical trial
Following last week’s deal that saw Impression Healthcare (ASX: IHL) secure the cannabinoid materials it needs to conduct a series of clinical trials, the cannabis company has announced that it has su...
Impression Healthcare secures long term oil supply agreement, unveils new cannabis discovery brand Incannex
Impression Healthcare (ASX: IHL) has moved to extend its medicinal cannabis market coverage after unveiling the all-new cannabinoid drug discovery brand Incannex Pharmaceuticals.
As a new entity, I...
Impression Healthcare becomes official supplier and research partner to ONE Championship
Barely a week after Aurora announced a deal with the Ultimate Fighting Championship (UFC), Australia’s very own Impression Healthcare (ASX: IHL) has made a move that emulates one of Canada’s most prom...
Impression Healthcare appoints leading medicinal cannabis pioneer Dr Sud Agarwal to its board
Impression Healthcare (ASX: IHL) has tweaked its internal structure by appointing Dr Sud Agarwal, a leading figure in the medicinal cannabis industry as its chief medical officer and non-executive dir...
